Navigation Links
Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
Date:11/30/2007

ns in blood pressure than either drug alone. This, along with its favorable side-effect profile, should make AZOR an attractive treatment option for patients whose blood pressure does not respond to either component drug in isolation. U.S. approval was granted in September 2007.

While the reason for menopause remains unknown, KV Pharmaceutical believes EvaMist, which takes the third spot on the list, may offer significant advantages to women experiencing menopause. This product is a small, easy-to- use hand-held applicator that delivers a pre-set metered dose via the skin, releasing estradoil into the bloodstream over 24 hours. EvaMist gained FDA approval in July 2007.

The first of two potential treatments for cancer on the list of notable drugs gaining approval this quarter is Yondelis, developed by PharmaMar for patients who have not responded to previous regimens in their treatment of soft tissue sarcoma. Yondelis is the first approved product from PharmaMar, a Spanish biotech specializing in cancer drugs derived from marine organisms and has Orphan Drug status in both the EU and U.S., securing extended protection against generic competition.

The second approval win for Novartis this quarter, Tasigna, is an orally available inhibitor of Bcr-Abl, c-Kit, PDGF-R and related receptor tyrosine kinases for the potential treatment of various types of leukemia. Though the drug has been approved only in Switzerland for chronic myeloid leukemia, it is awaiting approval in the U.S. and Japan and has been recommended for approval across the EU.

Following are the top five drugs in each category of phase changes:

The Five Most Promising Drugs Entering Phase III Trials

* bevasiranib sodium, (Wet AMD), Opko

* recombinant active glucocerebrosidase, (Gaucher's disease), Protalix

* odanacatib, (osteoporosis), Merck & Co

* laquinimod, (multiple sclerosis), Active Biotech/Teva

* elesclomol, (solid tumors), Synta
'/>"/>

SOURCE Thomson Scientific
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Thomson Scientific Predicts Nobel Laureates
2. Thomson Scientific Announces BONDplus for Biological Researchers
3. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
4. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
5. Thomson Healthcare Endorsed as Preferred Vendor of Information Products and Services for Virginia Hospitals
6. Thomson Acquires Prous Science
7. Common Early-Warning Symptoms of Ovarian Cancer Identified in CDC/Thomson Healthcare Study
8. Thomson Scientific Ranks Australian Universities and Research Institutes
9. Thomson Healthcare Study Finds That Hospitals Delivering High-Quality Heart Care Are Efficient and Cost Effective, Too
10. Thomson Scientific Launches Confessions ... of a User Campaign Asking Are You the New Face of Research?
11. Contract Renewal Extends Thomson Healthcares Long-Standing Relationship with University Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... By Steven Reinberg ... -- A device intended to help with weight loss by ... to meet expectations in a trial among obese patients. ... between the brain and stomach, researchers hoped to suppress feelings ... they anticipated. "A device that safely blocks the nerve ...
(Date:9/2/2014)... ANGELES (Sept. 2, 2014) Measuring the levels of sex ... a sudden cardiac arrest, a heart rhythm disorder that is ... study, published online by the peer-reviewed journal Heart Rhythm ... sex hormone, were found in men who had a sudden ... hormone, were strongly associated with greater chances of having a ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Evolve ... within the primary and urgent care arena, is ... opening coincides with a health fair the clinic ... incorporating technology to assist patients in achieving high ... Medical Clinics’ pricing structure is a groundbreaking change ...
(Date:9/2/2014)... York, NY (PRWEB) September 02, 2014 ... soccer tickets. The first week in September will be ... Teams from Brazil, Colombia, Mexico, Chile, Ecuador and Bolivia ... The following matches will take place between September 5th - ... Stadium on Tuesday, September 9th , Mexico vs. ...
(Date:9/2/2014)... your outpatient doctor does not know? Or when ... but your doctor does not have the right ... incomplete communication from hospitals to outpatient primary care ... lead to hospital readmissions. , However, a ... hospitals, communication during patient care transitions. Researchers from ...
Breaking Medicine News(10 mins):Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 2Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 3Health News:Study links sex hormone levels in the blood to risk of sudden cardiac arrest 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 3Health News:Ticket Down Substantially Slashes Ticket Prices on Brazil vs. Ecuador Tickets, Brazil vs. Colombia Tickets, Mexico vs. Chile Tickets and Mexico vs. Bolivia Tickets 2Health News:Ticket Down Substantially Slashes Ticket Prices on Brazil vs. Ecuador Tickets, Brazil vs. Colombia Tickets, Mexico vs. Chile Tickets and Mexico vs. Bolivia Tickets 3Health News:Can data motivate hospital leaders to improve care transitions? 2
... Integrated Medical,Systems, Inc., a medical technology systems integrator ... that it has received,510(k) clearance from the U.S. ... 1000(TM) "suitcase" intensive care unit (ICU)., "FDA ... accomplishment for the,company as we continue to demonstrate ...
... PhD.,co-founder and Chief Scientific Officer of Posit Science, has ... announcement by the Institute,today. Dr. Merzenich is one of ... a highly selective process that recognizes,people who have made ... care, and public health. Election is considered one of ...
... Oct. 13 The 2008 NCPA Digest,sponsored by ... 110th Annual,Convention. The Digest has been published annually ... portrait of the financial state of,independent community pharmacy ... an inside look into how the Medicare Part ...
... Knowledge Sharing among Physicians, MOUNTAIN VIEW, Calif., ... the healthcare IT market, Frost & Sullivan recognizes,Infor-Med, ... Sullivan Award for,Technology Innovation for its novel Praxis(R) ... EMR Knowledge Exchanger., The Praxis(R) EMR system ...
... 13 NeoVista, Inc., presented,yesterday the anatomic ... on choroidal neovascular lesions in an analysis ... 26th Annual Meeting. The,12-month data presented by ... Houston, Texas, demonstrated anatomic improvements on both,angiography ...
... neonatology fellows have been awarded grants designed to ... follow-up care of the premature infant as part ... MedImmune,s commitment to expanding research within pediatric medicine, ... totaling $175,000 in research funding. The five recipients ...
Cached Medicine News:Health News:Integrated Medical Systems Receives FDA Clearance for World's First 'Suitcase' Intensive Care Unit 2Health News:Integrated Medical Systems Receives FDA Clearance for World's First 'Suitcase' Intensive Care Unit 3Health News:Merzenich Elected to Institute of Medicine 2Health News:Merzenich Elected to Institute of Medicine 3Health News:Positive Picture of Independent Community Pharmacies Emerges With Release of 2008 NCPA Digest, Sponsored by Cardinal Health 2Health News:Positive Picture of Independent Community Pharmacies Emerges With Release of 2008 NCPA Digest, Sponsored by Cardinal Health 3Health News:Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology 2Health News:Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology 3Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 2Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 3Health News:MedImmune grants 5 new fellowships to help expand premature infant follow-up care research 2
(Date:9/2/2014)... , Sept. 2, 2014 Reportlinker.com announces ... its catalogue: Asia - Pacific Minimally ... http://www.reportlinker.com/p02353212/Asia---Pacific-Minimally-Invasive-Surgery-Spinal-Device-Market.html The growth rate of the ... device market will remain at double-digit levels throughout the ... as the future of this field. The ...
(Date:9/2/2014)... , Sept. 2, 2014 The Pharmaceutical Care ... benefit managers (PBMs), today filed a lawsuit in ... new Iowa law that restricts ... for the state,s employers and consumers.  ... by severely restricting the use of Maximum Allowable Cost ...
(Date:9/2/2014)... BARCELONA , Spanien und CALGARY, Alberta ... Vorgestellt in der "State of the ... Kardiologenverbandes 2014    Resverlogix Corp. (TSX: RVX) ... of Medical Affairs bei Resverlogix, beim Kongress des europäischen ... Spanien, einen Vortrag gehalten hat. In seinem Vortrag mit ...
Breaking Medicine Technology:Asia - Pacific Minimally Invasive Surgery Spinal Device Market 2Asia - Pacific Minimally Invasive Surgery Spinal Device Market 3Asia - Pacific Minimally Invasive Surgery Spinal Device Market 4Asia - Pacific Minimally Invasive Surgery Spinal Device Market 5Asia - Pacific Minimally Invasive Surgery Spinal Device Market 6Asia - Pacific Minimally Invasive Surgery Spinal Device Market 7Asia - Pacific Minimally Invasive Surgery Spinal Device Market 8Asia - Pacific Minimally Invasive Surgery Spinal Device Market 9Asia - Pacific Minimally Invasive Surgery Spinal Device Market 10Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 3RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 4RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 5RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 6
... DIEGO, May 4, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ... 2011 financial results after the NASDAQ Global Select Market closes ... Arena,s President and Chief Executive Officer, will host a conference ... Pacific Time) to discuss the financial results for the first ...
... ULURU Inc. (NYSE AMEX: ULU) ... with the U.S. Food and Drug Administration to obtain ... containing wound care products represent a growing segment of ... and contributes to new tissue development. Collagen dressings encourage ...
Cached Medicine Technology:Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10 3ULURU Inc. Announces the Filing of a 510(k) Application for Altrazeal® Collagen 2
Ergotec Vetriretinal Instrument System. Reverse action jaws. 0.4 mm cupped tips....
Designed to securely hold scleral plugs during insertion and removal. The cross action handle is designed to reduce hand fatigue while grasping plug....
For use with the Landers Vitrectomy Lens set (MVS 1079A). Shafts angled 45 degrees with curved grooved blades for holding the Landers vitrectomy lenses. Polished finish....
Ergotec Vetriretinal Instrument System. Ultra-fine angled tips (4 mm) with 20 gauge shaft. 25 mm in length. Overall length from rear rotation knob to tip....
Medicine Products: